Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9280440 | 1.00 | POLB (0.69) | POLBALDH1A1CASP1HSD17B10FKBP1A | |
| SCHEMBL9275930 | 0.89 | POLB (0.54) | POLBALDH1A1FKBP1AMAPTTSHR | |
| SCHEMBL9275925 | 0.89 | POLB (0.54) | POLBALDH1A1FKBP1AMAPTTSHR | |
| SCHEMBL9275466 | 0.88 | POLB (0.62) | POLBALDH1A1CYP3A4CYP2C9MEN1 | |
| SCHEMBL9275456 | 0.88 | POLB (0.62) | POLBALDH1A1CYP3A4CYP2C9MEN1 | |
| SCHEMBL9280380 | 0.85 | ALPG (0.54) | POLBALDH1A1HSD17B10FKBP1AMAPT | |
| SCHEMBL9280373 | 0.85 | ALPG (0.54) | POLBALDH1A1HSD17B10FKBP1AMAPT | |
| SCHEMBL9280775 | 0.83 | FKBP1A (0.72) | POLBFKBP1A | |
| SCHEMBL9280780 | 0.83 | FKBP1A (0.72) | POLBFKBP1A | |
| SCHEMBL3567330 | 0.81 | KMT2A (0.72) | POLBALDH1A1MAPTTSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193762-B2 | Selective inhibitors of prolylcarboxypeptidase | UNIVERSITY OF MISSISSIPPI (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI | 2013-11-21 | — | — | US | disclosed |
| WO-2012075287-A2 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | PREP, PEPD, DPEP1 | POLB 2633/4885ALDH1A1 859/4885CASP1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.